Belgian biopharmaceutical group UCB has entered into a major licensing agreement with China-based Antengene for an experimental autoimmune disease therapy, in a deal that could surpass $1.1 billion in total value.

Under the agreement, UCB will pay $60 million upfront for rights to ATG-201, a therapy targeting B-cell-related autoimmune diseases. Additional milestone payments tied to development progress and commercial performance, along with royalties on future net sales, could push the total value well above $1 billion.

Shares of Antengene rose about 6% in Hong Kong trading following the announcement, reflecting investor optimism around the strategic partnership.

Focus on B-Cell Autoimmune Diseases

ATG-201 is designed to treat autoimmune conditions driven by B-cell dysfunction, an area of increasing focus within immunology research. B cells play a central role in antibody production, and therapies targeting these cells have shown promise in diseases such as lupus and multiple sclerosis.

Antengene plans to submit clinical trial applications in Australia and China during the first quarter of 2026. After completion of Phase I trials, UCB will assume responsibility for further global development.

The agreement also includes access to associated manufacturing technology, giving UCB control over production as the program advances.

Strategic Expansion for UCB

For UCB, the deal strengthens its immunology pipeline and reinforces its strategy of expanding in high-value autoimmune indications. The company has been actively pursuing innovative biologic and next-generation immune therapies to diversify revenue streams beyond its established portfolio.

By securing worldwide development and commercialization rights, UCB positions itself to capture long-term global value if ATG-201 progresses successfully through clinical trials.

Platform Validation for Antengene

Antengene described the partnership as validation of its development platform capabilities. Out-licensing early-stage assets to established global pharma players is a common strategy among biotech firms seeking to monetize innovation while sharing development risk.

Milestone-based structures also reduce upfront capital burden for the licensing partner while aligning incentives around clinical success.

As autoimmune therapies remain one of the most competitive and lucrative areas in drug development, the collaboration underscores sustained investment in immunology innovation across global markets.